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Background: Our primary objective was to establish a cutoff value for the soluble fms-like tyrosine kinase 1(sFlt-1)/
placental growth factor (PlGF) ratio measured using the Elecsys assay to predict late-onset preeclampsia in low-risk
pregnancies. Our secondary objective was to evaluate the ability of combination models using Elecsys data, second
trimester uterine artery (UtA) Doppler ultrasonography measurements, and the serum fetoplacental protein levels
used for Down’s syndrome screening, to predict preeclampsia.
Methods: This prospective cohort study included 262 pregnant women with a low risk of preeclampsia. Plasma
levels of pregnancy-associated plasma protein-A (PAPP-A) and serum levels of alpha-fetoprotein, unconjugated
estriol, human chorionic gonadotropin, and inhibin-A were measured, and sFlt-1/PlGF ratios were calculated.
All women underwent UtA Doppler ultrasonography at 20 to 24 weeks of gestation.
Results: Eight of the 262 women (3.0%) developed late-onset preeclampsia. Receiver operating characteristic curve
analysis showed that the third trimester sFlt-1/PlGF ratio yielded the best detection rate (DR) for preeclampsia at a
fixed false-positive rate (FPR) of 10%, followed by the second trimester sFlt-1/PlGF ratio, sFlt-1 level, and PlGF level.
Binary logistic regression analysis was used to determine the five best combination models for early detection of
late-onset preeclampsia. The combination of the PAPP-A level and the second trimester sFlt-1/PlGF ratio yielded a
DR of 87.5% at a fixed FPR of 5%, the combination of second and third trimester sFlt-1/PlGF ratios yielded a DR of
87.5% at a fixed FPR of 10%, the combination of body mass index and the second trimester sFlt-1 level yielded a
DR of 87.5% at a fixed FPR of 10%, the combination of the PAPP-A and inhibin-A levels yielded a DR of 50% at a
fixed FPR of 10%, and the combination of the PAPP-A level and the third trimester sFlt-1/PlGF ratio yielded a DR
of 62.5% at a fixed FPR of 10%.
Conclusions: The combination of the PAPP-A level and the second trimester sFlt-1/PlGF ratio, and the combination
of the second trimester sFlt-1 level with body mass index, were better predictors of late-onset preeclampsia than
any individual marker.
Keywords: Preeclampsia, Soluble fms-like tyrosine kinase, Placental growth factor, sFlt-1, PlGF, sFlt-1/PlGF ratio,
PAPP-A, BMI, Low-risk population* Correspondence: chadh001@chamc.co.kr
†Equal contributors
1Department of Obstetrics and Gynecology, CHA Gangnam Medical Center,
CHA University, Seoul, Republic of Korea
3Department of Obstetrics and Gynecology, CHA Gangnam Medical Center,
650-9 Yeoksam-dong, Gangnam-gu, Seoul, Republic of Korea
Full list of author information is available at the end of the article
© 2014 Park et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Park et al. BMC Pregnancy and Childbirth 2014, 14:35 Page 2 of 11
http://www.biomedcentral.com/1471-2393/14/35Background
Preeclampsia is characterized by hypertension and signi-
ficant proteinuria during pregnancy. This multisystem dis-
order occurs in approximately 3% of pregnancies [1], and
can progress to eclampsia with life-threatening seizures.
Recent evidence indicates that there are numerous
phenotypes of preeclampsia, indicating that a number of
pathophysiologic mechanisms related to the mother and
fetus may contribute to the timing of disease onset [2].
Preeclampsia has been described as two distinct disease
entities: early-onset preeclampsia, which develops before
34 weeks of gestation, and late-onset preeclampsia, which
develops at or after 34 weeks of gestation [3]. Early-onset
preeclampsia is strongly associated with deficient tropho-
blast invasion and failure of normal spiral artery remodel-
ing. Late-onset preeclampsia may be caused by increased
maternal vascular susceptibility to the normal inflam-
matory state of pregnancy or atherosis of a placenta that
initially developed normally [4].
Preeclampsia is one of the leading causes of mater-
nal mortality worldwide, and in developed countries it
increases perinatal mortality five-fold [5]. Chronic hyper-
tension, pregestational diabetes mellitus, multifetal preg-
nancy, and preeclampsia during a previous pregnancy are
associated with a three- to five-fold increased risk of
preeclampsia [6]. This high-risk population tends to
develop severe or early preeclampsia, and accounts for
about one-third of cases of early-onset preeclampsia [7].
Patients at high risk of preeclampsia usually undergo close
surveillance during pregnancy, and can be referred to
specialized centers for perinatal care. Women at low risk
of preeclampsia also need close surveillance, and detection
and prompt management of these patients can improve
maternal and fetal mortality and morbidity. However,
there is no reliable screening test for early identification of
late-onset preeclampsia in low-risk pregnancies. Combin-
ation of the clinical, biochemical, and biophysical markers
is likely to increase the predictive power of screening
examinations.
It has been suggested that placental soluble fms-like
tyrosine kinase 1 (sFlt-1) is a causative factor in pre-
eclampsia. sFlt-1 acts as a potent vascular endothelial
growth factor (VEGF) and placental growth factor
(PlGF) antagonist by binding to these molecules and
thereby reducing the free circulating levels of VEGF and
PlGF. Decreased levels of circulating VEGF and PlGF ap-
pear to result in reversal of physiological vasodilation,
leading to hypertension [8]. Several studies have repor-
ted that the sFlt-1/PlGF ratio can be used to identify
patients at risk of preeclampsia [9,10]. Verlohren et al.
[9] reported that a sFlt-1/PlGF ratio of ≥ 85 (Elecsys;
Roche Diagnostics GmbH, Mannheim, Germany) predic-
ted preeclampsia. However, a lower cutoff value could
yield a more sensitive diagnostic test.In high-risk women, persistently increased uterine artery
(UtA) resistance during the first half of pregnancy is asso-
ciated with a high risk of early-onset preeclampsia [7]. A
combination of UtA Doppler ultrasonography measure-
ments (pulsatility index and mean arterial pressure) and
biochemical markers at 11 to 13 weeks of gestation
effectively identified women at high risk of hyperten-
sive disorders in pregnancy [11]. Yu et al. [12] reported
that in low-risk pregnancies, preeclampsia associated with
delivery at or beyond 34 weeks of gestation was most
effectively predicted by a combination of ultrasonography
findings and maternal factors. However, the ability of vari-
ous biophysical markers to predict preeclampsia in low-
risk pregnancies should be examined more thoroughly.
The integrated test for fetal Down’s syndrome uses
a combination of placental biomarkers. Among these
markers, the levels of pregnancy-associated plasma
protein (PAPP-A) and inhibin-A are positively associ-
ated with subsequent preeclampsia [13-16]. However, the
screening efficacy of these markers for preeclampsia re-
mains to be determined. This study evaluated the ability
of the PAPP-A and inhibin-A levels, sFlt-1/PIGF ratio,
and UtA Doppler ultrasonography measurements to pre-
dict preeclampsia in low-risk pregnancies, and established




This prospective study analyzed the risk of preeclampsia
according to the results of blood sample analyses in
pregnant women at low risk of preeclampsia. The study
included women who received regular antenatal care at
the prenatal care unit of Cha Hospital in Seoul, Korea
between April 2011 and December 2011. All patients
were recruited before 10 weeks of gestation, based on
measurement of the fetal crown-rump length. All sub-
jects underwent the integrated test for fetal Down’s syn-
drome, UtA Doppler ultrasonography at 20 to 24 weeks
of gestation, and calculation of the sFlt-1/PlGF ratio at
24 to 27 and 34 to 37 weeks of gestation. Women were
excluded if they were aged ≥ 40 years or had a multifetal
pregnancy, chronic hypertension, prior history of pre-
eclampsia, pregestational diabetes mellitus, gestational
diabetes mellitus, delivery before 35 weeks of gestation,
early-onset preeclampsia (before 35 weeks of gestation),
or body mass index (BMI) ≥ 25 kg/m2. All the cases of
preeclampsia included in the study were diagnosed with
severe preeclampsia after 35 weeks of gestation (late-on-
set preeclampsia), and the time of diagnosis was almost
the same as the time of delivery.
Preeclampsia was defined according to the National High
Blood Pressure Education Program Working Group on
High Blood Pressure in Pregnancy criteria. Hypertension
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ments of ≥ 140 mmHg (Korotkoff phase 1) and diastolic
blood pressure measurements of ≥ 90 mmHg (Korotkoff
phase 5). Proteinuria was defined as ≥ 300 mg of protein
in a 24-hour urine collection sample, or repeated ≥ 1+
proteinuria on dipstick urinalysis [17]. Preeclampsia
was defined as severe if (1) the systolic blood pres-
sure was > 160 mmHg or the diastolic blood pressure
was > 110 mmHg on at least two occasions after 20
weeks of gestation, or (2) there was ≥ 5 g of protein
in a 24-hour urine collection specimen or ≥ 3+ proteinuria
on dipstick urinalysis of two samples collected at least
4 hours apart. The time of onset of preeclampsia was
defined as the date of diagnosis. Normal pregnancy
was defined as term delivery with no documented
concerns regarding hypertension or proteinuria before
or after delivery.
Ethics statement
All women provided written informed consent before
the collection of blood samples. The collection and use
of samples for the purposes of this study were approved
by the Institutional Review Board of CHA Gangnam
Medical Center, CHA University.
Laboratory methods
All women underwent the integrated test for fetal
Down’s syndrome. Maternal serum samples were ob-
tained at 11+0 to 13+6 and 15+0 to 20+6 weeks of gesta-
tion for measurement of the plasma PAPP-A level and
the serum levels of the quadruple test markers: alpha-
fetoprotein (MSAFP), unconjugated estriol, human
chorionic gonadotropin (hCG), and inhibin-A. Markers
were measured using a UniCel DxI 800 analyzer (Beck-
man Coulter Inc., Fullerton, CA, USA) and the values
were transformed to multiples of the median (MoM)
after adjusting for gestational age and maternal BMI.
To measure the plasma levels of sFlt-1 and PlGF,
venous blood was collected in silicon-coated glass tubes
at 24+0 to 27+6 and 34+0 to 37+6 weeks of gestation. After
clotting, the samples were centrifuged and plasma was
stored at −80°C. The sFlt-1 and PlGF levels of each
sample were measured simultaneously using the fully
automated Roche Diagnostics Elecsys assay (Roche
Diagnostics, Penzberg, Germany), and the sFlt-1/PlGF
ratio was calculated.
Uterine artery Doppler ultrasonography
UtA Doppler transabdominal ultrasonography with color
flow mapping was performed at 20 to 24 weeks of gesta-
tion. The bilateral UtA Doppler impedance indices were
recorded according to the Fetal Medicine Foundation
guidelines [12], including the mean pulsatility index,
resistance index, systolic/diastolic ratio, and notching.Statistical analysis
Data are expressed as the median (range) and were ana-
lyzed using non-parametric methods.
Weighted log10-linear regression was used to calculate
the median values for the levels of sFlt-1, PlGF, PAPP-A,
alpha-fetoprotein (MSAFP), β-hCG, unconjugated estriol,
and inhibin-A, and the highest uterine artery pulsatility
index, mean uterine artery pulsatility index, highest uter-
ine artery resistance index, mean uterine artery resistance
index, and nuchal translucency thickness, as a function of
fetal crown-rump length and maternal weight for the 254
subjects without preeclampsia. The results for all subjects
were then expressed as MoM values. Repeated analysis of
variables was used to calculate the effects of gestational
age on variables. Receiver operating characteristic (ROC)
curve analysis was used to determine the detection rate
(DR) of each marker for subsequent late-onset preeclamp-
sia at a fixed false-positive rate (FPR). Logistic regression
analysis was used to calculate the a posteriori risk of
preeclampsia for each patient using the panel of available
markers expressed in terms of MoM and parity.
The logistic regression equation used was ln(y) =
α + β1χ1 + β2χ2 +… βnχn where α is the constant of the
model (the odds of preeclampsia without risk factors or
when the risk factors assume the lowest risk value), β is
the coefficient associated with the risk factor, χ is the
risk factor, and y is the odds of preeclampsia. Therefore,
odds = exp(y) and risk = odds/(1 + odds).
Analyses were performed using the Statistical Package
for the Social Sciences version 19.0 (SPSS Inc., Chicago,
IL, USA) and Power Analysis and Sample Size version
11 (NCSS LLC, Kaysville, UT, USA).
Results
A total of 262 women were enrolled in this study, of
which 8 developed late-onset preeclampsia. The charac-
teristics of subjects with and without preeclampsia and
the distributions of the studied markers are shown in
Table 1. There were significant differences in maternal
weight before pregnancy and at delivery, BMI, infant
birth weight, and parity between patients with and
without preeclampsia. The BMI before pregnancy was
significantly higher (p = 0.010), infant birth weight was
significantly lower (p < 0.001), and delivery time was sig-
nificantly earlier (p < 0.001) in patients with preeclampsia
than in patients without preeclampsia. Small-for-ges-
tational-age infants (birth weight below the 10th per-
centile) were significantly more frequent in patients
with preeclampsia than in patients without preeclamp-
sia (p = 0.006). The MoM values of all the biochemical
markers except for the MSAFP level, and of nuchal
translucency thickness, were significantly different be-
tween patients with and without preeclampsia (Table 2).
UtA Doppler ultrasonography measurements were not
Table 1 Characteristics of the subjects
Variables Preeclampsia (n = 8) Unaffected group (n = 254) P‐value *
Maternal age, yrs 33 (25–37) 33 (20–39) 0.872
Nulliparous, % 66.1 50 0.779
Prepregnancy weight (kg) 62 (50–71) 53 (40–75) 0.018
BMI, kg/m2, mean 22.9 (19.05–24.86) 20.2 (15.24–24.9) 0.010
Weight at delivery 78 (61.7–107) 65 (43.5–102.2) 0.007
Infant birth weight,gm 2385 (1760–3100) 3160 (2100–4000) <0.001
Small for gestational age(%) 37.5 8.7 0.006
Gestational age at delivery 35.5 (35–40) 38.5 (35–41) <0.001
Data are expressed as median (minimum–maximum) or percentage.
*Mann–Whitney U Test or Fisher’s test.
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preeclampsia. Figure 1 shows the results of repeated mea-
sures analysis of variance comparing the second and third
trimester sFlt-1/PlGF ratios in patients with and without
preeclampsia. The ratios were significantly associated with
time (within-subjects effect) and the development ofTable 2 Distributions of the variables of interest
variable Preeclampsia (n = 8)
Median gestational age (weeks) 11 (10–13)
PAPP-A, MoM 0.63 (0.34–1.67)
NT, MoM 1.05 (0.81–1.28)
Median gestational age 16 (15–17)
MSAFP, MoM 1.00 (0.41–4.38)
hCG,MoM 1.66 (1.16–2.68)
uE3, MoM 0.97 (0.69–1.28)
Inhibin A, MoM 1.86(0.82–2.96)
Median gestational age 26 (24–27)
sFlt-11, (pg/ml) 2360 (932–4435)
PlGF1, (pg/ml) 219 (34.25–698)
sFlt-1/PlGF1 11.9 (1.7–70.9)
Median gestational age 34 (34–36)
sFlt-12, (pg/ml) 6275 (4307–12835)
PlGF2, (pg/ml) 115.9 (16.48–284.9)
sFlt-1/PlGF2 76.3 (15.1–352.7)
Uterine artery doppler
Mean RI 0.55 (0.48–0.77)
Mean PI 0.94 (0.71–1.86)
Mean SD 2.25 (1.95–4.25)
Highest RI 0.58 (0.53–0.77)
Highest PI 1.03 (0.79–1.86)
Highest SD 2.40 (2.10–4.30)
Notch (%) 0.4
Data are expressed as median (minimum–maximum).
PAPP-A: pregnancy-associated plasma protein-A, NT: nuchal translucency thickness,
unconjugated estriol, sFlt-11: second trimester sFlt-1, PlGF1: second trimester PlGF, s
PlGF2: third trimester PlGF, sFlt-1/PlGF2: thirst trimester sFlt-1/PlGF ratio.preeclampsia (between-subjects effect) (both p < 0.001,
sphericity test).
The univariate ROC curve analyses for each of the
variables evaluated are shown in Table 3. The third
trimester sFlt-1/PlGF ratio yielded the highest DR of
























MSAFP: alpha-fetoprotein, hCG: human chorionic gonadotropin, uE3:
Flt-1/PlGF1: second trimester sFlt-1/PlGF ratio, sFlt-12: third trimester sFlt-1,
Figure 1 Slope of the sFlt-1/PlGF ratio. Results of repeated measures analysis of variance comparing the second trimester sFlt-1/PlGF ratio
(sFlt-1/PlGF1) with the third trimester sFlt-1/PlGF ratio (sFlt-1/PlGF2). Dotted line: patients with preeclampsia, solid line: patients without preeclampsia.
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(p = 0.001). Of the single markers, the sFlt-1 level
yielded the best DR (75%) at a fixed FPR of 10%,
followed by the PlGF level (62.5%) and the PAPP-A
level (50%). Even though the number of preeclampsia
cases was small, the two-tailed power of the data with
a Type I error rate of 5% ranged from 86% to 99% for all
the ROC curves. For logistic regression analysis, an odds
ratio of > 2.5 was required to achieve sufficient power with
a type I error rate of 5% at the given incidence of pre-
eclampsia (8/262, 3%). Figure 2 shows the univariate ROC
curves for the second and third trimester sFlt-1/PlGF
ratios, which had the best performance for predicting
preeclampsia out of the available markers.
Multivariate ROC curves were constructed using the
logistic regression analysis results (Table 4). The best
performances were achieved by the combination of the
PAPP-A level and the second trimester sFlt-1/PlGF ratio,
and the combination of the second and third trimester
sFlt-1/PlGF ratios. It is worth noting that the combinationTable 3 Univariate ROC curve analysis for each marker and th
false-positive rate (FPR) of 10% and 5%
Variable Cutoff1 DR1 Cutoff2 DR2
BMI, kg/m2 23.6 37.5 24.3 25
PAPP-A, MoM 0.58 50 0.49 50
Inhibin A, MoM 1.76 50 2.18 50
sFlt-11, (pg/ml) 2358 75 3064 25
sFlt-12 4680 75 6040 50
PlGF1, (pg/ml) 257 62.5 200 37.5
PlGF2 113.4 50 86.5 37.5
sFlt-1/PlGF1 6.05 75 7.0 75
sFlt-1/PlGF2 28.2 87.5 43.7 50
Cutoff1: cutoff value at a fixed FPR of 10%, DR1: DR at a fixed FPR of 10%, Cutoff2: c
pregnancy-associated plasma protein-A, sFlt-11: second trimester sFlt-1, PlGF1: secon
trimester sFlt-1, PlGF2: third trimester PlGF, sFlt-1/PlGF2: third trimester sFlt-1/PlGF rof the PAPP-A level and the second trimester sFlt-1/PlGF
ratio had a DR of 87.5% (at a fixed FPR of 10%), and the
second trimester sFlt-1/PlGF ratio alone had a DR of 75%
(at a fixed FPR of 10%). The addition of BMI to the second
trimester sFlt-1 level increased the DR from 75% to 87.5%.
The DR of the combination of the second and third
trimester sFlt-1/PlGF ratios was not improved by the
addition of any other marker. Interestingly, the cutoff for
high risk of preeclampsia was similar for each of the five
models, ranging from 2.2% to 5%. Figure 3 shows mul-
tivariate ROC curves for combination models. Pattern
analysis results for the cases detected by the logistic
models are shown in Table 5 (right columns) and Table 6.
Three cases were detected by three of the models: the
combination of the PAPP-A level and second trimester
sFlt-1/PlGF ratio, the combination of the BMI and the
second trimester sFlt-1 level, and the combination of the
second and third trimester sFlt-1/PlGF ratios. Two cases
were detected by all five models. The combination of the
PAPP-A and inhibin-A levels failed to detect two of thee detection rate (DR) for preeclampsia at a fixed
Area SE p-value 95% CI
0.769 0.086 0.010 0.600 0.937
0.707 0.116 0.046 0.480 0.935
0.780 0.095 0.007 0.593 0.967
0.842 0.080 0.001 0.686 0.998
0.944 0.020 <0.001 0.906 0.983
0.751 0.103 0.016 0.549 0.953
0.847 0.060 0.001 0.729 0.965
0.851 0.092 0.001 0.670 1.000
0.939 0.033 <0.001 0.873 1.000
utoff value at a fixed FPR of 5%, DR2: DR at a fixed FPR of 5%, PAPP-A:
d trimester PlGF, sFlt-1/PlGF1: second trimester sFlt-1/PlGF ratio, sFlt-12: third
atio, SE: standard error.
Figure 2 Univariate ROC curves for the second and third trimester sFlt-1/PlGF ratios. The second trimester sFlt-1/PlGF ratio (sFlt-1/PlGF1)
and third trimester sFlt-1/PlGF ratio (sFlt-1/PlGF2) were the best markers for predicting preeclampsia.
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were each detected by at least two models (Table 6). Parity
(nulliparous versus parous) did not add any discriminatory
power and was therefore excluded from the logistic
models. The risk estimates for each of the eight cases of
preeclampsia according to the logistic models are shown
in Table 5. The different models provided quite different
risk estimates for preeclampsia for the same patient. For
example, Cases 4 and 218 had a risk estimation range of
more than 90% (from 0.59% to 99.32% and from 5.46% to
99.99%, respectively). This indicates that more cases need
to be evaluated in future prospective studies to identify
the best cutoff values for detecting patients at high risk of
preeclampsia.
Discussion
This study used combinations of maternal and biochemical
markers to identify women at high risk of preeclampsia in
a low-risk population. We focused on late-onset pre-
eclampsia in a low-risk population because the prevalenceTable 4 ROC curve analyses for combinations of markers and
using a logistic regression model
Variable Cutoff1 DR1 Cutoff2 DR
PAPP-A + Inhibin A 5.01% 50 9.19% 37
PAPP-A + sFlt-1/PlGF1 2.85% 87.5 4.72% 87
PAPP-A + sFlt-1/PlGF2 2.62% 62.5 4.07% 50
BMI + sFlt-11 4.6% 87.5 8.9% 75
sFlt-1/PlGF1 + sFlt-1/PlGF2 2.2% 87.5 3.4% 87
The exploratory variable in each case is the risk determined by the logistic equation
Cutoff1: cutoff value at a fixed FPR of 10%, DR1: DR at a fixed FPR of 10%, Cutoff2: c
pregnancy-associated plasma protein-A, sFlt-11: second trimester sFlt-1, sFlt-1/PlGF1
SE: standard error.of late-onset preeclampsia is much higher than the pre-
valence of early-onset preeclampsia [18]. Early-onset
preeclampsia is usually associated with placental dysfunc-
tion, reduction in placental volume, intrauterine growth
restriction, abnormal uterine and umbilical artery Doppler
ultrasonography findings, low birth weight, multi-organ
dysfunction, perinatal death, and adverse maternal and
neonatal outcomes [19,20]. Late-onset preeclampsia is
more often associated with a normal placenta, larger pla-
cental volume, normal fetal growth, normal uterine and
umbilical artery Doppler ultrasonography findings, normal
birth weight, and more favorable maternal and neonatal
outcomes [19,21,22]. Considering the heterogeneous
pathophysiology, no single screening test is sufficient for
predicting preeclampsia.
Our results indicate that combination of the Elecsys
sFlt-1/PlGF ratio with the pre-pregnancy BMI and
biochemical markers during pregnancy may improve the
sensitivity of predicting preeclampsia in a low-risk
population. The DRs for individual markers ranged fromthe DR for preeclampsia at a fixed FPR of 10% and 5%
2 Area S E p-value 95% CI Variable
.5 0.812 0.093 0.003 0.629 0.995
.5 0.969 0.015 <0.001 0.940 0.999
0.917 0.036 <0.001 0.847 0.988
0.937 0.039 <0.001 0.861 1.000
.5 0,946 0.043 <0.001 0.862 1.000
.
utoff value at a fixed FPR of 5%, DR2: DR at a fixed FPR of 5%, PAPP-A:
: second trimester sFlt-1/PlGF ratio, sFlt-1/PlGF2: third trimester sFlt-1/PlGF ratio,
Figure 3 Multivariate ROC curves for combination models. PAPP-A + sFlt-1/PlGF1, BMI + sFlt-11, and sFlt-1/PlGF1 + sFlt-1/PlGF2 were the best
combinations for predicting preeclampsia. PAPP-A: pregnancy-associated plasma protein-A, sFlt-11: second trimester sFlt-1, sFlt-1/PlGF1: second
trimester sFlt-1/PlGF ratio, sFlt-1/PlGF2: third trimester sFlt-1/PlGF ratio.
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75% for a fixed FPR of 5%. After combining markers, the
estimated DR ranged from 50% to 87.5% for a fixed FPR
of 10%, and from 37.5% to 87.5% for a fixed FPR of 5%.
Combining markers had a moderate benefit at a fixed
FPR of 5%. The second and third trimester sFlt-1 levels
had the highest DRs among the single markers, but the
sFlt-1/PlGF ratio was a stronger predictor of preeclamp-
sia than either marker alone. The third trimester sFlt-1/
PlGF ratio had the highest DR of the individual variables
evaluated, but was not sufficient as a single screening
method for early detection of preeclampsia.
ROC curve analysis showed that BMI was the strongest
clinical predictor of preeclampsia with a DR of 37.5% at aTable 5 Estimated risk (%) for each case of preeclampsia for e
Cases ID PAPP-A + Inhibin A PAPP-A + sFlt-1/PlGF1 PAPP-A + sFlt-1
38 4.43 2.59 55.44
51 18.64 4.76 2.62
147 2.86 5.40 1.62
137 36.53 33.60 38.30
144 2.96 36.02 3.11
4 0.59 99.32 1.88
218 5.46 99.99 80.35
153 26.96 100 99.92
*0 =missed case, 1 = detected case.
PAPP-A: pregnancy-associated plasma protein-A, sFlt-11: second trimester sFlt-1, PlG
sFlt-12: third trimester sFlt-1, PlGF2: third trimester PlGF, sFlt-1/PlGF2: third trimesterfixed FPR of 10% and a DR of 25% at a fixed FPR of 5%. A
previous study reported that increased early pregnancy
insulin resistance was independently associated with sub-
sequent preeclampsia [23]. We found that BMI predicted
preeclampsia (p = 0.010) at a cutoff value of 23.64 kg/m2
at a fixed FPR of 10% and 24.26 kg/m2 at a fixed FPR of
5%, even in a low-risk population with BMI < 25 kg/m2.
This result is consistent with previous reports that
obese women are at increased risk of developing pre-
eclampsia [24,25].
Duckitt and Harrington [26] performed a systematic
review of 52 studies and found that nulliparity was a risk
factor for preeclampsia (relative risk: 2.91). A prospect-
ive cohort study also found that nulliparous women hadach model at a fixed FPR of 10%
/PlGF2 BMI + sFlt-11 sFlt-1/PlGF1+ sFlt-1/PlGF2 Pattern*
0.79 7.25 0 0 1 0 1
5.30 0.64 1 1 1 1 0
51.4 19.85 0 1 0 1 1
19.1 31.95 1 1 1 1 1
42.9 20.90 0 1 1 1 1
40.3 97.83 0 1 0 1 1
20.8 99.99 1 1 1 1 1
30.6 100 1 1 1 1 1
F1: second trimester PlGF, sFlt-1/PlGF1: second trimester sFlt-1/PlGF ratio,
sFlt-1/PlGF ratio.
Table 6 Patterns analysis for detection of preeclampsia for each model at a fixed FPR of 10%
Number of cases Detection model of preeclampsia*
PAPP-A + Inhibin A PAPP-A + sFlt-1/PlGF1 PAPP-A + sFlt-1/PlGF2 BMI + sFlt-11 sFlt-1/PlGF1 + sFlt-1/PlGF2
1 0 0 1 0 1
2 0 1 0 1 1
1 0 1 1 1 1
1 1 1 1 1 0
3 1 1 1 1 1
*0 =missed case, 1 = detected case.
PAPP-A: pregnancy-associated plasma protein-A, sFlt-11: second trimester sFlt-1, PlGF1: second trimester PlGF, sFlt-1/PlGF1: second trimester sFlt-1/PlGF ratio,
sFlt-12: third trimester sFlt-1, PlGF2: third trimester PlGF, sFlt-1/PlGF2: third trimester sFlt-1/PlGF ratio.
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higher risks of uterine artery notching and gestational
hypertensive disorders than other women [27]. However,
no association between preeclampsia and parity was ob-
served in this study (p = 0.779). This difference may re-
sult from differences in ethnicity and marital status
between the subjects in the different studies, or the rela-
tively small number of cases in this study.
The integrated test for fetal Down’s syndrome is based
on the levels of several first and second trimester feto-
placental markers. PAPP-A is a large, highly glycosylated
protein that is produced by developing trophoblast cells.
PAPP-A has been shown to be a syncytiotrophoblast-
derived insulin-like growth factor binding protein protease
[28]. A multicenter study of 8,839 women demonstrated
a significant relationship between a PAPP-A level at or
below the 5th percentile and intrauterine growth restric-
tion, preterm delivery, preeclampsia, and stillbirth [13].
Inhibin-A is a glycoprotein hormone that is a member of
the transforming growth factor-β family. The placenta is
the primary source of this circulating protein during
pregnancy, and its concentration increases in the third
trimester of uncomplicated pregnancies [29]. Although an
increased serum inhibin-A level is significantly associ-
ated with subsequent preeclampsia, the inhibin-A level
has poor sensitivity for predicting preeclampsia [14,15].
Nevertheless, we found that the inhibin-A level was a
more sensitive marker for predicting subsequent pre-
eclampsia than the hCG level in the second trimester.
Addition of the hCG level to the inhibin-A level did not
improve the screening efficacy for preeclampsia in a previ-
ous study [16]. Significantly lower PAPP-A levels and
higher inhibin-A and hCG levels were observed in women
who developed preeclampsia than in those who did not,
but the levels of unconjugated estriol and MSAFP had no
predictive power. At a fixed FPR of 10% and 5%, the
PAPP-A and inhibin-A levels both had DRs of 50%. In our
hospitals, the integrated test for fetal Down’s syn-
drome is routinely offered to all women. This test inclu-
des the PAPP-A level at 11 to 13 weeks of gestation andthe inhibin-A level at 15–20 weeks of gestation. These
biochemical markers for Down’s syndrome could poten-
tially be used to improve the prediction of preeclampsia.
Recent studies have shown that UtA Doppler wave-
form analysis can identify women at risk of adverse
pregnancy outcomes in the second trimester [30-32]. As
described above, abnormal placentation is considered to
play a central role in the pathogenesis of preeclampsia.
Shallow cytotrophoblast interstitial invasion and failure
of endovascular invasion result in increased vascular
resistance and decreased placental perfusion [32]. How-
ever, this mechanism is more relevant in early-onset
preeclampsia than in late-onset preeclampsia. A recent
study proposed that 22 to 25 weeks of gestation is the
best time for predicting preeclampsia by uterine artery
Doppler velocimetry data [33]. Costa et al. [34] reported
that second trimester UtA Doppler ultrasonography
measurements had high sensitivity for predicting pre-
eclampsia in a low-risk population, but only a 29% posi-
tive predictive value. A low positive predictive value for
late-onset disease can complicate screening in a low-risk
population. In our study, we found no significant associ-
ation between UtA Doppler ultrasonography measure-
ments and preeclampsia. Our small sample size and the
fact that all cases of preeclampsia were late-onset disease
might have contributed to our failure to detect a signifi-
cant association between UtA Doppler ultrasonography
measurements and preeclampsia.
The Elecsys system is an immunoassay system that
measures plasma sFlt-1 and PlGF levels. Although it was
developed for diagnostic testing of patients with pre-
eclampsia, a carefully established cutoff value could poten-
tially enable detection of subclinical preeclampsia. A
recent study demonstrated patients with preeclampsia or
the syndrome of hemolysis, elevated liver enzymes, and
low platelet count with a high sFlt-1/PlGF ratio were at
significantly increased risk of imminent delivery, and the
authors proposed that the sFlt-1/PlGF ratio be used as a
prognostic marker [10]. In our study, blood samples for
the Elecsys assay were collected at 24+0 to 27+6 and 34+0
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of 25% at a fixed FPR of 10%, and a DR of 75% at a fixed
FPR of 5%. The PlGF level yielded a lower DR than the
sFlt-1 level at a fixed FPR of 5%, in the first trimester but
not in the second trimester. The second trimester sFlt-1/
PlGF ratio yielded a DR of 75% at a fixed FPR of 10%
(cutoff value: 6.05) and 5% (cutoff value: 7.0). The third
trimester sFlt-1/PlGF ratio yielded a DR of 87.5% at a fixed
FPR of 10% (cutoff value: 28.15) and a DR of 50% at a
fixed FPR of 5% (cutoff value: 43.70). The Elecsys ins-
tructions recommend using an sFlt-1/PlGF ratio of > 85
(independent of gestational age) for diagnosing preeclamp-
sia. The results of this study show that the sFlt-1/PlGF
ratio is a useful predictor of late-onset preeclampsia.
Ohkuchi et al. [35] reported that a cutoff value of 45 for
the Elecsys sFlt-1/PlGF ratio gave 100% sensitivity and 95%
specificity for detecting preeclampsia in a Japanese popula-
tion. Soto et al. [36] reported that women with late-onset
preeclampsia had significantly lower PlGF and soluble
VEGF receptor-2 levels, lower PlGF/soluble endoglin and
PlGF/soluble VEGF receptor-1 ratios, and higher soluble
VEGF receptor-1 and soluble endoglin levels than
normal pregnant women. Evidence of an imbalance
between angiogenic and anti-angiogenic factors in
preeclampsia has consistently been observed in women
of Hispanic, Caucasian, Asian, African, and African-
American origin, and therefore appears to be a consistent
finding of this disorder [36].
In this study, small-for-gestational-age infants were
usually associated with preeclampsia. In patients without
preeclampsia, the median sFlt-1/PlGF ratio at 34 to 37
weeks of gestation was low but had a very wide range
(median: 8; range: 0.8–156). Four patients had an sFlt-1/
PlGF ratio of > 85. Among these patients, the mean UtA
pulsatility index was above the 95th percentile for gesta-
tional age [37] in only one case with a small-for-gesta-
tional-age infant.
In this study, the combination of the second and
third trimester sFlt-1/PlGF ratios and the combination
of the PAPP-A level and the second trimester sFlt-1/
PlGF ratio yielded the best DRs. The sFlt-1/PlGF ratio
measured shortly before delivery at or beyond 34
weeks of gestation has little value as a screening test,
because delivery is an effective treatment for late-
onset preeclampsia. However, if the second trimester
sFlt-1/PlGF ratio is equivocal and the patient does
not have preeclampsia at 34 weeks of gestation, serial
measurements may help clinicians to detect and manage
emerging late-onset preeclampsia. The combination of the
PAPP-A level and the second trimester sFlt-1/PlGF ratio
is therefore the best marker for early detection of late-
onset preeclampsia.
Akolekar et al. [38] developed an effective first-
trimester screening model for preeclampsia using theUtA pulsatility index, mean arterial pressure, and PAPP-
A and PlGF MoM values. Their algorithms detected
95.3% of cases of early-onset preeclampsia and 45.6% of
cases of late-onset preeclampsia at a fixed FPR of 10.9%.
Saxena et al. [39] reported that the mean third trimester
sFlt-1 level was significantly higher (p = 0.002), and the
mean first trimester sFlt-1 level was significantly lower
(p = 0.03), in women who developed preeclampsia than
in women with normal pregnancies. The serial measure-
ments of the sFlt-1/PlGF ratio used in this study enabled
a much higher rate of detection of late-onset preeclamp-
sia than the 45.6% described above.
A weak point of our study is the different risk estima-
tion results obtained when different combinations of
markers were used in the same subject. This is probably
due to the low number of patients with preeclampsia,
and the fact that preeclampsia results from various path-
ophysiologic mechanisms that may alter the markers in
different ways. However, three of the eight cases were
detected by all the models used, and all the cases were
detected by at least two of the models. The strong points
of the study include its prospective design and the evalu-
ation of several markers for predicting preeclampsia.
The combinations used in this study appear to have
higher predictive accuracy than the combination of first-
trimester maternal risk factors and mean arterial pres-
sure used in the large prospective study by Poon et al.
[40], which reported a 52% detection rate for preeclamp-
sia at a 10% false-positive rate. A larger number of
patients may have resulted in different accuracy rates for
the combinations evaluated in our study. However, there
was a steep increase in the sFlt-1/PlGF ratio in patients
with preeclampsia (Figure 1), which is consistent with
previously reported results [41], and we expect that the
main conclusions would not change with a larger study
population. Although the slope of the sFlt-1/PlGF ratio
was not used in our algorithms, this value may be
useful for enhancing predictive accuracy in a future larger
scale study.
Conclusions
The Elecsys sFlt-1/PlGF ratio allows identification of
low-risk pregnancies at high risk of developing pre-
eclampsia. A cutoff value of 6.05 in the second tri-
mester and 28.15 in the third trimester had the best
ability to predict preeclampsia at a fixed FPR of 10%.
The PAPP-A level and BMI can be used in combination
with the sFlt-1/PlGF ratio to increase the rate of detection
of preeclampsia. Further studies are required to assess the
usefulness of our combined screening test in low-risk
populations.
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